Stock Track | ARS Pharmaceuticals Soars 5.07% on neffyinSchools Program Launch for Needle-Free Epinephrine in Schools

Stock Track2024-12-05

ARS Pharmaceuticals Inc (SPRY) saw its stock soar 5.07% in Wednesday's intraday trading session, outperforming the broader market. This surge comes after the company announced the planned launch of its "neffyinSchools" program in January 2025.

The neffyinSchools program aims to provide eligible public and private K-12 schools in the U.S. with free doses of neffy, ARS Pharmaceuticals' recently approved needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis. Each participating school will receive two cartons (four single-use doses) of neffy 2mg for adults and children weighing over 66 lbs.

This initiative is expected to drive wider adoption and usage of neffy in schools across the country, potentially saving lives by ensuring prompt access to epinephrine in cases of severe allergic reactions. Investors appear to view the neffyinSchools program as a positive development that could expand neffy's market reach and boost future sales growth for ARS Pharmaceuticals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124471356?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-05 04:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124471356","market":"us","top_or_hot":-1,"title":"Stock Track | ARS Pharmaceuticals Soars 5.07% on neffyinSchools Program Launch for Needle-Free Epinephrine in Schools","media":"Stock Track","content":"<p>ARS Pharmaceuticals Inc (SPRY) saw its stock soar 5.07% in Wednesday's intraday trading session, outperforming the broader market. This surge comes after the company announced the planned launch of its \"neffyinSchools\" program in January 2025.</p>\n\n<p>The neffyinSchools program aims to provide eligible public and private K-12 schools in the U.S. with free doses of neffy, ARS Pharmaceuticals' recently approved needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis. Each participating school will receive two cartons (four single-use doses) of neffy 2mg for adults and children weighing over 66 lbs.</p>\n\n<p>This initiative is expected to drive wider adoption and usage of neffy in schools across the country, potentially saving lives by ensuring prompt access to epinephrine in cases of severe allergic reactions. Investors appear to view the neffyinSchools program as a positive development that could expand neffy's market reach and boost future sales growth for ARS Pharmaceuticals.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ARS Pharmaceuticals Soars 5.07% on neffyinSchools Program Launch for Needle-Free Epinephrine in Schools</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ARS Pharmaceuticals Soars 5.07% on neffyinSchools Program Launch for Needle-Free Epinephrine in Schools\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-05 04:42 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ARS Pharmaceuticals Inc (SPRY) saw its stock soar 5.07% in Wednesday's intraday trading session, outperforming the broader market. This surge comes after the company announced the planned launch of ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1124471356","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124471356","pubTimestamp":1733344944,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ARS Pharmaceuticals Inc  saw its stock soar 5.07% in Wednesday's intraday trading session, outperforming the broader market. This surge comes after the company announced the planned launch of its \"neffyinSchools\" program in January 2025.The neffyinSchools program aims to provide eligible public and private K-12 schools in the U.S. with free doses of neffy, ARS Pharmaceuticals' recently approved needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, including an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"股票追踪ARS Pharmaceuticals因neffyinSchools在学校推出无针肾上腺素计划而飙升5.07%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":1},"content_text":"ARS Pharmaceuticals Inc (SPRY) saw its stock soar 5.07% in Wednesday's intraday trading session, outperforming the broader market. This surge comes after the company announced the planned launch of its \"neffyinSchools\" program in January 2025.\nThe neffyinSchools program aims to provide eligible public and private K-12 schools in the U.S. with free doses of neffy, ARS Pharmaceuticals' recently approved needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis. Each participating school will receive two cartons (four single-use doses) of neffy 2mg for adults and children weighing over 66 lbs.\nThis initiative is expected to drive wider adoption and usage of neffy in schools across the country, potentially saving lives by ensuring prompt access to epinephrine in cases of severe allergic reactions. Investors appear to view the neffyinSchools program as a positive development that could expand neffy's market reach and boost future sales growth for ARS Pharmaceuticals.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124471356"}